New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
Myriad Genetics (NASDAQ: MYGN) has released findings from its Cancer Risk Survey revealing important insights about women's attitudes toward health screenings. The survey found that while 80% of women fear screenings, 75% would find genetic testing reassuring when facing health concerns.
The study highlighted that 37% of women believe genetic testing can help manage breast health, but 40% were unaware of genetic testing tools for breast cancer risk assessment. Only 14% of respondents have undergone genetic testing, despite over 25% of women in OB/GYN settings meeting hereditary cancer testing criteria.
The survey also revealed that while 50% of respondents consider parental health history important, only 30% knew their parents' health history well. Myriad's MyRisk® Hereditary Cancer Test with RiskScore® combines genetic insights, family history, and clinical factors to calculate breast cancer risk.
Myriad Genetics (NASDAQ: MYGN) ha pubblicato i risultati della sua indagine sul rischio di cancro, rivelando importanti dati sull'atteggiamento delle donne verso gli screening sanitari. L'indagine ha mostrato che mentre l'80% delle donne teme gli screening, il 75% ritiene che un test genetico sarebbe rassicurante di fronte a preoccupazioni sulla salute.
Lo studio ha evidenziato che il 37% delle donne pensa che i test genetici possano aiutare a gestire la salute del seno, ma il 40% ignorava l'esistenza di strumenti genetici per valutare il rischio di cancro al seno. Solo il 14% dei rispondenti ha svolto un test genetico, nonostante oltre il 25% delle donne in ambito OB/GYN soddisfi i criteri per il test per i tumori ereditari.
L'indagine ha anche rilevato che sebbene il 50% degli intervistati consideri importante la storia sanitaria dei genitori, solo il 30% la conosce bene. Il MyRisk® Hereditary Cancer Test con RiskScore® di Myriad combina dati genetici, la storia familiare e fattori clinici per calcolare il rischio di cancro al seno.
Myriad Genetics (NASDAQ: MYGN) ha publicado los resultados de su Encuesta sobre el Riesgo de Cáncer, revelando datos importantes sobre la actitud de las mujeres hacia las pruebas de detección. La encuesta halló que mientras el 80% de las mujeres teme las pruebas, el 75% consideraría tranquilizador un test genético ante preocupaciones de salud.
El estudio destacó que el 37% de las mujeres cree que las pruebas genéticas pueden ayudar a gestionar la salud mamaria, pero el 40% desconocía las herramientas de prueba genética para evaluar el riesgo de cáncer de mama. Solo el 14% de las personas encuestadas se ha sometido a una prueba genética, a pesar de que más del 25% de las mujeres en entornos OB/GYN cumple los criterios para pruebas de cáncer hereditario.
La encuesta también reveló que, aunque el 50% de los encuestados considera importante el historial de salud parental, solo el 30% conoce bien la historia de sus padres. El MyRisk® Hereditary Cancer Test con RiskScore® de Myriad combina información genética, antecedentes familiares y factores clínicos para calcular el riesgo de cáncer de mama.
Myriad Genetics (NASDAQ: MYGN)가 자사의 암 위험 설문조사 결과를 발표하여 여성들의 건강 검진에 대한 태도에 대한 중요한 통찰을 제시했습니다. 조사 결과 여성의 80%가 검진을 두려워하는 반면, 75%는 건강 고민 시 유전자 검사가 안심이 될 것이라고 답했습니다.
연구에서는 여성의 37%가 유전자 검사가 유방 건강 관리에 도움이 될 수 있다고 믿는 반면, 40%는 유방암 위험 평가를 위한 유전자 검사 도구를 알지 못했습니다. 응답자 중 단 14%만이 유전자 검사를 받은 경험이 있으며, OB/GYN 환경에 있는 여성의 > 25% 이상이 유전성 암 검사 기준에 해당함에도 불구하고 검사 경험은 적었습니다.
설문은 또한 응답자의 50%가 부모의 건강 이력을 중요하게 여기지만, 단 30%만이 부모의 건강 이력을 잘 알고 있다는 점을 밝혔습니다. Myriad의 MyRisk® Hereditary Cancer Test with RiskScore®는 유전 정보, 가족력 및 임상적 요인을 결합해 유방암 위험도를 계산합니다.
Myriad Genetics (NASDAQ: MYGN) a publié les résultats de son enquête sur le risque de cancer, apportant des informations importantes sur l'attitude des femmes envers les dépistages. L'étude a révélé que si 80% des femmes craignent les dépistages, 75% trouveraient rassurant un test génétique en cas d'inquiétude pour leur santé.
L'étude a souligné que 37% des femmes estiment que les tests génétiques peuvent aider à gérer la santé des seins, mais que 40% ignoraient l'existence d'outils de dépistage génétique pour évaluer le risque de cancer du sein. Seules 14% des personnes interrogées ont subi un test génétique, alors que plus de 25% des femmes en consultation OB/GYN remplissent les critères pour un test des cancers héréditaires.
L'enquête a également montré que si 50% des répondants jugent important l'antécédent médical parental, seulement 30% le connaissent bien. Le MyRisk® Hereditary Cancer Test avec RiskScore® de Myriad combine des données génétiques, les antécédents familiaux et des facteurs cliniques pour calculer le risque de cancer du sein.
Myriad Genetics (NASDAQ: MYGN) hat die Ergebnisse seiner Cancer Risk Survey veröffentlicht und damit wichtige Erkenntnisse zur Einstellung von Frauen gegenüber Gesundheits-Screenings geliefert. Die Umfrage ergab, dass zwar 80% der Frauen Screenings fürchten, aber 75% genetische Tests als beruhigend empfinden würden, wenn sie gesundheitliche Sorgen haben.
Die Studie zeigte, dass 37% der Frauen glauben, genetische Tests könnten bei der Brustgesundheit helfen, während 40% nichts über genetische Testmöglichkeiten zur Einschätzung des Brustkrebsrisikos wussten. Nur 14% der Befragten haben einen Gentest durchgeführt, obwohl mehr als 25% der Frauen in gynäkologischen/geburtshilflichen Einrichtungen die Kriterien für einen Test auf hereditären Krebs erfüllen.
Die Umfrage ergab außerdem, dass zwar 50% der Befragten die Gesundheitsgeschichte der Eltern für wichtig halten, aber nur 30% diese gut kennen. Myriads MyRisk® Hereditary Cancer Test mit RiskScore® kombiniert genetische Erkenntnisse, Familienanamnese und klinische Faktoren, um das Brustkrebsrisiko zu berechnen.
- 75% of women find genetic testing reassuring for health concerns
- MyRisk® test offers comprehensive breast cancer risk assessment combining multiple factors
- Survey reveals opportunity for expanding genetic testing adoption in eligible population
- 80% of women report fear of health screenings
- 40% of women lack awareness about genetic testing tools
- Only 14% of respondents have undergone genetic testing despite higher eligibility
- 70% of respondents don't know their parents' health history well
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing
SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While
“Many women find health screenings—like mammograms, blood work, genetic testing—scary because they may be afraid of the unknown: ‘what if something’s wrong?’ On the other hand, they may intellectually understand that these screenings are important healthcare tools,” said Ifeyinwa Stitt, MD, OB/GYN and medical director, Caronette Fibroid & Pelvic Wellness Center Annapolis, MD. “My advice is to overcome the fear of the unknown—especially with genetic testing as this information could ultimately help us save their lives.”
The survey showed that more than one in three respondents (
“Genetic tests—like the MyRisk® Hereditary Cancer Test with RiskScore®—can provide valuable information about a patient’s hereditary risk for certain cancers. This information opens the door for additional screenings like more frequent mammograms and/or MRIs,” said Dr. Stitt. “This survey demonstrates the need for more and clearer conversations about genetic testing and how it can be integrated into a woman’s overall health care plan.”
_______________
1 Waldman, et al. 2024
The importance of family health history—and how it may help with screening
Along with additional screenings, knowing family cancer history is an important factor in calculating cancer risk. More than
Familial factors important to understand include multiple cancers in the family, the age at which a family member was diagnosed and whether the cancer was rare, such as pancreatic or ovarian cancer. Knowing this information can indicate that a person may benefit from hereditary cancer testing.
By combining genetic insights, family history and other clinical factors, the MyRisk Hereditary Cancer Test with RiskScore calculates a woman’s five-year and lifetime risk of breast cancer. If a woman is found to be at high risk, she then has multiple options available to her, including a change in medical management, such as earlier or increased frequency of screenings. For more information about understanding your risk of breast cancer, visit GetMyRisk.com.
About the Cancer Risk Survey
The nationwide survey was conducted online by ACUPOLL Precision Research, Inc. between April 9–22, 2025. The responding samples were comprised of:
- n=1,002 English-language proficient non-institutionalized US adult females who were recruited to represent the general US population sampled from an existing national general population research panel
- n=404 Adult females who met hereditary cancer risk testing criteria were also recruited so as to better understand attitudes and perceptions of this audience sampled from the same national general population research panel
The Margin of Error is +/-
ACUPOLL has more than 30 years’ experience conducting statistically valid research through careful recruiting and the utilization of numerous quality control measures.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential for genetic testing to provide valuable information about a patient’s hereditary risk for certain cancers, which may lead to additional screenings and ultimately help physicians save lives. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
What did Myriad Genetics' (MYGN) Cancer Risk Survey reveal about women's attitudes toward screenings?
How many women are currently using genetic testing according to Myriad Genetics' survey?
What is Myriad Genetics' MyRisk Hereditary Cancer Test with RiskScore?
What percentage of women know their family health history according to MYGN's survey?
How can genetic testing help with breast health management according to the Myriad survey?
